Public data on the drug supply chain
The easiest way to counteract opacity is transparency. Each analysis here answers one question about who pays what for drugs in the United States, from federal filings, with the method and the data open.
The employers paying one company for both
256 self-funded health plans buy pharmacy benefits and medical administration from the same conglomerate. 3.34 million employees, $629 million in disclosed PBM compensation. The arrangement has shrunk from 417 plans since 2021; the headcount has not. Every row links to the Form 5500 filing.
Does acquisition cost fall after Cost Plus adds a generic?
1,069 generics Cost Plus added, against 773 it never carried. Raw, they cost pharmacies 10.5% less a year later. Most of that gap was opening before entry. The effect holds only for generics over $1 a unit.
One molecule, eight Medicare prices, one cash price
Medicare Part B pays $2.35 to $13.15 per milligram of ustekinumab depending on the label. Two biosimilars cost more than the drug they copy. All 101 US biosimilars, priced against their reference product.
Who your employer pays for pharmacy
Every self-funded plan with 1,000 or more employees that names its PBM and discloses the fee, arranged by metro area. Each row carries the signed federal filing behind it.
The markup, measured
What Cost Plus charges above pharmacy acquisition cost across its matched catalog, next to the retail price it displays beside each drug.
Injectables in shortage, and who makes them
Drugs currently in shortage by molecule, how many manufacturers each one has, and which countries hold the registered plants.
Generics radar
Brand drugs losing exclusivity within 24 months, ranked by current federal spending, with the patent and exclusivity dates behind each one.
What commercial plans pay per unit
The drug mix behind employer coverage and the amount paid per unit, measured against what pharmacies pay to acquire the same drugs.
Where the pharmacies are not
Counties ranked by pharmacies per 10,000 people, independent share, and closures, set against CDC social vulnerability.
The list keeps going
More analyses are in the pipeline. If one of these would be more useful sooner, or the question you want answered is not on this list, write and say so.